Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide
Xin Chen1, Lalage M Wakefield2, Joost J Oppenheim3
1Basic Science Program; Leidos Biomedical Research, Inc.; Frederick National Laboratory for Cancer Research; Frederick, MD USA ; Laboratory of Molecular Immunoregulation; Cancer Inflammation Program; Center for Cancer Research; National Cancer Institute; Frederick, MD USA.
Abstract:
In a mouse model of breast carcinoma, the combination of cyclophosphamide and transforming growth factor β1,2,3 (TGFβ1,2,3)-targeting antibody achieved superior antineoplastic effects. This novel paradigm of synergistic chemoimmunotherapy promises to improve the clinical outcome of cancer patients with micrometastases, and thus deserves further investigation.
Related Concept Videos
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Tumor Microenvironment


